Clinical Trials
2 trialsNCT06149481 2026-06-05
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06253494 2026-04-09
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting